Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, août 28
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Twist Bioscience Corp
TWST
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$153.10
3.04
2.03%
À la clôture: Aug 27, 5:00 PM EST
$153.00
-0.1
-0.07%
Après les heures: 6:32 PM EST
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Twist Bioscience Financials
Twist Bioscience (TWST) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Twist Bioscience Q3 EPS $(0.56) Misses $(0.50) Estimate, Sales $118.376M Beat $114.490M Estimate
Benzinga Newsdesk
PRO
Twist Bioscience Raises FY2026 Sales Guidance from $442.000M-$447.000M to $456.000M-$457.000M vs $446.103M Est
Twist Bioscience (NASDAQ:TWST) raises FY2026 sales outlook from $442.000 million-$447.000 million to $456.000 million-$457.000 million vs $446.103 million estimate.
Benzinga Newsdesk
PRO
Twist Bioscience Sees Q4 Sales $123.000M-$124.000M vs $117.546M Est
Twist Bioscience (NASDAQ:TWST) sees Q4 sales of $123.000 million-$124.000 million vs $117.546 million analyst estimate.
Benzinga Newsdesk
These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results
Twist Bioscience Corp (TWST) reported Q2 loss but exceeded sales guidance. CEO expects profitability and raised FY sales guidance. Analysts raise price targets.
Avi Kapoor
AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens
Twist Bioscience posts wider Q2 loss, beats revenue estimates, raises FY26 outlook, and expands gene portfolio.
Vandana Singh
PRO
Twist Bioscience Q2 Adj. EPS $(0.59) Misses $(0.48) Estimate, Sales $110.715M Beat $107.657M Estimate
Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.48) by 22.92 percent. This is a 10.61 percent increase over losses of $(0.66) per share
Benzinga Newsdesk
Privacy Manager